Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features

19 Jan 2024

Abstract excerpt

In the Antibody Mediated Prevention (AMP) trials (HVTN 704/HPTN 085 and HVTN 703/HPTN 081), prevention efficacy (PE) of the monoclonal broadly neutralizing antibody (bnAb) VRC01 (vs. placebo) against HIV-1 acquisition diagnosis varied according to the HIV-1 Envelope (Env) neutralization sensitivity to VRC01, as measured by 80% inhibitory concentration (IC80). Here, we performed a genotypic sieve analysis, a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to HIV/AIDS drug development and treatment
Share to HIV Research and Treatment

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38241441
DOI: 10.1073/pnas.2308942121

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence featuresPMID 38241441Read ↗

Neutralization profiles of HIV-1 viruses from the VRC01 Antibody Mediated Prevention (AMP) trialsSemantic proximity Read ↗

Resistance mutations that distinguish HIV-1 envelopes with discordant VRC01 phenotypes from multi-lineage infections in the HVTN703/HPTN081 trial: implications for cross-resistance.Semantic proximity Read ↗

Profiling a large HIV-1 elite neutralizer cohort reveals remarkable CD4bs bNAb for HIV-1 prevention and therapySemantic proximity Read ↗

Predicting the broadly neutralizing antibody susceptibility of the HIV reservoirSemantic proximity Read ↗

Accurate Prediction of Antibody Resistance in Clinical HIV-1 IsolatesSemantic proximity Read ↗

Accurate Prediction for Antibody Resistance of Clinical HIV-1 IsolatesSemantic proximity Read ↗

Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV preventionSemantic proximity Read ↗

Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env Immunogens by Putative VRC01 Neutralizing Antibody Precursors.Semantic proximity Read ↗

Sieve analysis in HIV-1 vaccine efficacy trials.Semantic proximity Read ↗

Determinants of HIV-1 broadly neutralizing antibody induction.Semantic proximity Read ↗

A Randomised Clinical Trial of the Safety and Pharmacokinetics of VRC07-523LS Administered via Different Routes and Doses (HVTN 127/HPTN 087)Semantic proximity Read ↗

Optimal Combinations of Broadly Neutralizing Antibodies for Prevention and Treatment of HIV-1 Clade C InfectionSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.